HBs antigene prevalence in blood donors and the risk of transfusion of hepatitis b at the central hospital of yaounde, cameroon

Dominique Noah Noah, Richard Njouom, Aimé Bonny, P. Pirsou, J. Meli, M. Biwole Sida

.

DOI: 10.4236/ojgas.2011.12004                

Abstract

Parenteral transmission of hepatitis B virus (HBV) during blood transfusion is not insignificant. Although blood transfusion safety has greatly improved over the last 15 years, the transfusion risk of HBV remains high in developing countries. In the context where blood transfusion safety is limited in some hospitals in Cameroon, the development of good and quality practice for blood donation, based on the use of the most sensitive techniques for the detection of infectious risk of blood donation should be a priority of health authorities. The aim of this paper is to document the epidemiology of HBV infection in the population of blood donors and to assess the risk of infection during blood transfusions at the Central Hospital Yaoundé (CHY), Ca- meroon. Methods: During a seven months period, 1000 volunteer donors were recruited prospectively at the blood bank of the CHY. Those included in the study were people aged from 18 years to 55 years without any particular medical history. Data collection was done through an investigation form. Samples were first analysed at the CHY and then Centre Pasteur of Cameroon. Results: Of the 1000 samples tested 108 (10.8%) were positive for HBs Ag. The male and the female sex represented 83.1% and 16.9% respectively. According to the age groups, 56.2% were 18 to 27 years, 30.5% were 28 years to 37 years, 10.4% were 38 years to 47 years and 29% were 48 years to 55 years. The 892 negative sera were analyzed for total anti-HBc antibodies of which 75.78% were positive and 24.56% negative. The 676 samples positive for anti-HBc antibody were retested for HBs Ag using enzyme immunoassay with a confidence level of 95%, between 52 and 82 positive tests were still positive, a proportion that vary between 7.64% and 12.14% (9.89% ± 2.25%). Conclusion: The prevalence rate of 10.8% found in our series is consistent with data in Cameroon. The infectious risk of transmission of HBV among blood donors remains a major problem (9.89% ± 2.25%) related to the test used.

Keywords

Infectious Risk; HBV; CHY

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Frexinos, J., Buscail, L., et al. (2003) Hépato-gastro- entérologie proctologie. MASSON, Paris, 5, 489.
[2]	Trepo, C., Zoulim, F., Traitement de l’hépatite, B. (2009) Progrès attendus. Gastroenterology Clinical Biology, 33, 811-817.
[3]	Parkin, D.M. (2001) Global cancer statistics in the year. Lancet Oncology, 2, 533-543. doi:10.1016/S1470-2045(01)00486-7
[4]	Hill, C. (2008) Doyon. La fréquence des cancers en France en 2005 : évolution de la mortalité depuis 1950 et résumé du rapport sur les causes de cancer. Bull Cancer, 95, 5-10.
[5]	Njonou, J., Kupfer, B., Kochan, B., Zekeng, L., Kaptue, L. and Matz, B. (2002) Hepatitis C virus infection and genotypes among human immunodeficiency virus high- risk group in Cameroon. Journal of Medical Virology, 66, 179-186. doi:10.1002/jmv.2128
[6]	Zerbou, E.K., Dalekos, G.N., Boumba, D.S. and Tsianos, E.V. (2001) Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3 year prospective study in Northwestern Greece. Transfusion, 41, 652-658. doi:10.1046/j.1537-2995.2001.41050652.x
[7]	Mbendi Nlombi, C., Longo-Mbenza, B., Mbendi Nsukini, S., Muyembe Tamfum, J.J., Situakibanza Nanituma, H. and Vangu Ngoma, D. (2001) Prévalence du vih et l’an- tiggène HBs chez les donneurs de sang, risque résiduel de contamination chez les receveurs de sang à Kinshasa-Est, République Démocratique du Congo. TropMédecine tropicale, 61, 139-142.
[8]	Behzad-Behbahani, A., Mafi-Nejad, S.Z., Tabei, K.B., Lanka-rani, A., Torab, A. and Moaddeb, A. (2006) Anti- HBc and HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian Journal of Medical Research, 123, 37-42.
[9]	Mbanya, D.N., Takam, D. and P Ndumbey, P.M. (2003) Serological findings amongst first-time blood donors in Yaounde, Cameroon: Is safe donation a reality or a myth? Transfusion Médecine, 13, 267-273. doi:10.1046/j.1365-3148.2003.00453.x
[10]	Zekeng, L. and Kaptue, L. (1990) Serologie HIV et por-tage de l’antigene HBs et Hbe chez les donneurs de sang au CHU de Yaounde Cameroun. Annales de la Societe′ Belge Médecine Tropicale, 70, 49-53.
[11]	Meffre, C., Le Strat, Y., Delarocque-Astagneau, E., Le-masson, J.M., Coste, D., Steinmetz, J., Antona, D., Du-bois, F., Warszawski, J., Meyer, J.F., Leiser, S., Giorda-nella, J.P., Gueguen, R., Landau, A. and Desenclos, J.C. (2006) Prevalence of hepatitis B in France, 2003-2004. 41th EASL Annual Meeting, Vienne, Austria.
[12]	Moreira Diop, T. (2003) Atelier sur introduction des nouveaux vaccins dans PEV en Afrique francophone, révision des connaissances et considération des besoins en formation. Saly, Sénégal.
[13]	Morris, S., Stephen, S., Kelly, B., et al. (2007) Prise en charge de l’hépatite B chronique: Lignes directrices con-sensuelles. Conférence 4-5, Toronto, Canada.
[14]	Degos, F. and Hépatite, B. (2004) Qui et quand vacciner? Tiré à part, Post U FMC-HGE 3-4, L26, 47-51.
[15]	Berrajah-Fki, L., Ben Halima, S., Guermazi, F., Hammami, A. and Karray-Hakim, H. (2006) Signification du profil sérologique “anticorps anti HBc isolés” chez 284 patients suspects d’être infectés par le virus de l’hépatite B. Annual Biology Clinical, 64, 451-455.
[16]	Caspari, G., Beyer, H.J., Elbert, G., et al. (1989) Unsatis-factory specificities and sensitivities of six enzyme im-munoassays for antibodies to hepatitis B core antigen. Journal of clinical Microbiology, 27, 2067-2072.
[17]	Hofer, M., Joller Jemelka, H.I., Grob, P.J. and Lüthy, R. (1998) Opravil mand the swiss HIV cohort study. Fre-quent chronic hepatitis B virus infection in HIV-infected patient positive for antibody to hepatitis B core antigen only. European Journal of Clinical Microbiology and In-fectious, 17, 6-13. doi:10.1007/BF01584356